Japan fast-breeder reactor may restart in Feb
TOKYO Aug 12 (Reuters) - Japan's experimental fast-breeder nuclear reactor will be restarted as early as February 2010 after repeated delays in final safety checks, the Japan Atomic Energy Agency (JAEA) said on Wednesday.
The 280-megawatt Monju plant, designed to produce more nuclear fuel than it consumes, has been shut since December 1995 following a massive leak of liquid sodium, just months after the reactor first started power transmission.
A JAEA spokesman said the company's top executive told the local Fukui Prefecture earlier in the day that the restart is scheduled by the end of March at the latest.
JAEA in January had postponed the restart schedule indefinitely from the previous target of February 2009 to take into account repair work on holes discovered in the reactor's auxiliary building and other safety checks.
The Monju plant is located in Fukui prefecture, 400 km (250 miles) west of Tokyo.
Fast-breeder reactors have been beset by technical difficulties and many countries have abandoned the costly programmes.
Monju is a cornerstone of resource-poor Japan's nuclear fuel cycle programme, with the government spending more than 860 billion yen ($9.02 billion) on it. ($1=95.35 Yen) (Reporting by Osamu Tsukimori; Editing by Joseph Radford)
- Tweet this
- Share this
- Digg this
- Comedian Joan Rivers remains in serious condition at N.Y. hospital
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- UPDATE 4-Iceland says eruption over, lifts all airspace restrictions
- Ukraine seeks to join NATO; defiant Putin compares Kiev to Nazis
- Swedish carrier backs out as first Bombardier CSeries operator
India's economy grew by a faster-than-expected 5.7 percent in the three months through June, its fastest pace in two-and-a- half years, helped by a rebound in manufacturing and mining sectors, government data showed on Friday. Full Article
Exclusive: Reliance plans $13 billion projects including new refinery. Full Article
In race for bigger margins, drug makers willing to lose the India "advantage". Full Article